Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The KHENERGYZE Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04165239
Recruitment Status : Recruiting
First Posted : November 15, 2019
Last Update Posted : November 15, 2019
Sponsor:
Collaborator:
Julius Clinical, The Netherlands
Information provided by (Responsible Party):
Khondrion BV

Brief Summary:

Mitochondrial diseases, estimated prevalence 1 in 4,300 adults, is caused by pathogenic mutations in genes finally encoding for mitochondrial proteins of the various enzyme complexes of the OXPHOS. Among these mutations, the 3243A>G nucleotide change in the mitochondrially encoded transfer RNALeu(UUR) leucine 1 gene (MT TL 1) is the most prevalent one. The OXPHOS dysfunction resulting from such mutations leads to increased production of reactive oxygen species (ROS), ultimately leading to irreversible oxidative damage of macromolecules, or to more selective and reversible redox modulation of cell signaling that may impact (adult) neurogenesis.

Despite advances in the understanding of mitochondrial disorders, treatment options are extremely limited and, to date, largely supportive. Therefore, there is an urgent need for novel treatments. KH176, a new active pharmaceutical ingredient (API), is an orally bio-available small molecule under development for the treatment of these disorders (see Section 1.4). The current study will further evaluate the effect of KH176 in various cognitive domains and evaluate the effect of different doses of KH176 (See Section 1.5).

In view of the growing recognition of the importance of mitochondrial function in maintaining cognitive processes in the brain, as well as the understanding of the safety profile and pharmacokinetics of KH176 following the two clinical studies described above, a more detailed study is indicated of the effects of KH176 in various cognitive domains, using the confirmed safe and well-tolerated KH176 dose of 100 mg bid, as well as a lower dose of 50 mg bid. The primary objective is an evaluation of KH176 in the attention domain of cognitive functioning, as assessed by the visual identification test score of the Cogstate computerised cognitive testing battery.


Condition or disease Intervention/treatment Phase
Mitochondrial Diseases Mitochondrial Myopathies Mitochondrial Encephalomyopathies MELAS Syndrome MIDD Drug: KH176 Drug: Placebo Phase 2

Detailed Description:
For this study, a 3 x 3 crossover design will be applied, i.e., with 3 treatments, 3 sequences and 3 periods, employing a Latin square assignment. Using this design, each subject will function as his/her own control. This will reduce variability and thus increase the chances of observing true effects between treatment periods (effects of treatment compared to placebo). In each treatment period, assessments will be performed at baseline prior to dosing and post dosing, enabling a change from baseline analysis and enabling the possibility to compare baseline conditions for each treatment period. The treatment period in each treatment is 28 days (4 weeks), which is supported by the pre-clinical toxicology program. In mouse studies, a 4-week period was sufficient to observe clinically relevant effects.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 27 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: The study will be a double-blind, randomised, placebo-controlled, multi-centre, three-way cross-over study. Twenty-seven subjects, with a confirmed mitochondrial DNA tRNALeu(UUR) 3243A>G mutation and with clinical signs of mitochondrial disease including attentional dysfunction, and fulfilling pre-defined cardiac exclusion criteria, will be randomised over three treatment sequences as assigned by Latin-square. Each group will have 3 treatment periods of 28 days each, separated by 14-day washout periods between treatments. During the 28-day treatment periods, subjects will receive bid oral administration of 50 mg KH176,100 mg KH176, or placebo in the sequence as applicable for the group.
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase IIb Double-blind, Randomised, Placebo-controlled, Multi-centre, Confirmative Three-way Cross-over Study on Cognitive Function With Two Doses of KH176 in Subjects With a Genetically Confirmed Mitochondrial DNA tRNALeu(UUR) m.3243A>G Mutation.
Actual Study Start Date : October 30, 2019
Estimated Primary Completion Date : July 2020
Estimated Study Completion Date : July 2020


Arm Intervention/treatment
Experimental: Treatment A
Oral administration of 50 mg KH176 twice daily
Drug: KH176
Oral administration of 50 mg KH176 twice daily
Other Name: Sonlicromanol

Experimental: Treatment B
Oral administration of 100 mg KH176 twice daily
Drug: KH176
Oral administration of 100 mg KH176 twice daily
Other Name: Sonlicromanol

Placebo Comparator: Treatment C
Oral administration of matching placebo twice daily
Drug: Placebo
Oral administration of matching placebo twice daily




Primary Outcome Measures :
  1. Cognitive functioning: Attention [ Time Frame: One month ]
    The attention domain score of cognitive functioning, as assessed by the visual identification test of the Cogstate computerised cognitive testing battery


Secondary Outcome Measures :
  1. Executive functioning [ Time Frame: One month ]
    The executive functioning domain score of cognitive functioning, as assessed by the Groton Maze Learning Test of the Cogstate computerised cognitive testing battery

  2. Psychomotor function [ Time Frame: One month ]
    The psychomotor functioning domain score of cognitive functioning, as assessed by the Groton Maze Learning Test of the Cogstate computerised cognitive testing battery

  3. Visual learning [ Time Frame: One month ]
    The visual learning domain score of cognitive functioning, as assessed by the One Card Learning Test of the Cogstate computerised cognitive testing battery

  4. Verbal learning [ Time Frame: One month ]
    The verbal learning functioning domain score of cognitive functioning, as assessed by the International Shopping List Test of the Cogstate computerised cognitive testing battery

  5. Test of Attentional Performance (TAP) [ Time Frame: One month ]
    Standardised test to evaluate alertness and mental flexibility

  6. Beck Depression Inventory [ Time Frame: One month ]
    21-question multiple-choice self-report inventory, for measuring the severity of depression

  7. Hamilton Anxiety and Depression Score (HADS) [ Time Frame: One month ]
    Subject-reported outcome measure and comprises 14 items equally divided over the two subscales anxiety (HADS-A) and depression (HADS-D)

  8. Newcastle Mitochondrial Disease Scale for Adults (NMDAS) [ Time Frame: One month ]
    Semi-quantitative clinical rating scale designed for mitochondrial disease. The rating scale explores several domains: current function, system specific involvement, current clinical assessment and quality of life

  9. Number of headache days [ Time Frame: One month ]
    Self report diary

  10. Pure Tone Audiometry (PTA) [ Time Frame: One month ]
    Standardized test measure individual hearing threshold levels

  11. University of Penn Smell Identification Test (UPSIT) [ Time Frame: One month ]
    Test to measure the individual's ability to detect odors at a suprathreshold level.

  12. Cognitive Failure Questionnaire (CFQ) [ Time Frame: One month ]
    Questionnaire to evaluate subjective cognitive functioning.

  13. Neuro-QoL Fatigue Short Form (quality in life in neurological disorders) [ Time Frame: One month ]
    8-item self assessment questionnaire evaluating the perception of fatigue and its impact in daily life activities



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  1. Males and females aged 18 years or older at screening.
  2. Ability and willingness to provide written Informed Consent prior to screening evaluations.
  3. Confirmed mitochondrial DNA tRNALeu(UUR) m.3243A>G mutation.
  4. Positive NMDAS score >10 at Screening.
  5. Three or more clinical features, with no other causative unifying diagnosis, found to commonly occur in subjects with a m.3243A>G mutation:

    • Deafness
    • Developmental delay
    • Diabetes Mellitus
    • Epilepsy
    • Gastrointestinal complaints
    • Progressive External Ophtalmoplegia (PEO) and retinopathy
    • Ataxia
    • Exercise intolerance
    • Fatigue
    • Migraine (with or without aura), specified by at least five attacks fulfilling diagnostic criteria B-D:

B. Headache attacks lasting 4-72 hours (untreated or unsuccessfully treated)

C. Headache has at least two of the following four characteristics:

  1. unilateral location
  2. pulsating quality
  3. moderate or severe pain intensity
  4. aggravation or causing avoidance of routine physical activity (e.g. walking or climbing stairs)

D. During headache at least one of the following:

  1. nausea and/or vomiting
  2. photophobia and phonophobia

6. Attentional dysfunction score (Cogstate Identification test) ≥ 0.5 standard deviations poorer than healthy controls at Screening.

7. Disease appropriate physical and mental health as established at Screening by medical history, physical examination, ECG and vital signs recording, and results of clinical chemistry and haematology testing as judged by the investigator.

8. Objectified Left Ventricular Ejection Fraction (LVEF) ≥45% (echocardiography, or otherwise).

9. Left Ventricular (LV) wall thickness ≤15 mm.

10. Left atrium dilatation ≤ 40 mL/m2. Note: No need to test LV parameters (criteria #7, #8, #9) if favourable echocardiography (or otherwise) results dated less than 6 months prior to Screening are available.

11. Women of childbearing potential must be willing to use adequate contraceptive methods during the entire study, i.e., a hormonal contraceptive method (pill, vaginal ring, patch, implant, injectable, hormone-medicated intrauterine device) or an intrauterine device. If a female subject is of childbearing potential and does not use any of these methods, male sex partners must use condoms plus spermicide, or must be confirmed azoospermic after vasectomy.

Note 1: Natural family planning methods, female condom, cervical cap or diaphragm are not considered adequate contraceptive methods in the context of this study.

Note 2: To be considered not of childbearing potential, potential female subjects must be post-menopausal for at least two years, or have been surgically sterilised (bilateral tubal ligation, hysterectomy or bilateral oophorectomy) for at least 6 months prior to Screening.

Note 3: Male subjects with female partners of childbearing potential do not need to take contraceptive precautions. KH176 has been shown non-genotoxic judged from the Ames test, Chromosomal Aberration test and in vivo Micronucleus test. Moreover, appreciable systemic exposure from the exposure to (~2.5 mL) semen is extremely unlikely.

12. Able to comply with the study requirements, including swallowing study medication.

Exclusion Criteria

  1. Surgery of gastro-intestinal tract that might interfere with absorption.
  2. Participation in a study of an investigational product in the preceding 3 months prior to the first dose or during this study.
  3. Documented history of ventricular tachycardia (HR>110 beats/min).
  4. (Family) history of acute heart failure, unexplained syncope or congenital long QT syndrome.
  5. Clinically relevant abnormal laboratory, vital signs or physical or mental health at Screening or Baseline as judged by the investigator.
  6. Clinically relevant abnormal ECG or cardiac functioning, defined as ST-segment elevation > 1 mm in I, II, III, aVL ,aVF ,V3 ,V4 ,V5 ,V6; > 2 mm in V1, V2; QTc > 450 ms (local, machine read), T-top inversion in >1 consecutive lead.
  7. Serum Hyper-potassium (> 5.0 mEq/L).
  8. Serum Hypo-potassium (< 3.5 mEq/L).
  9. History of ischemic heart disease.
  10. Symptomatic heart failure.
  11. Clinically relevant aorta and/or mitralis valvular defect as judged by the investigator.
  12. Pregnancy or breast feeding (females).
  13. Poor nutritional state as judged by the investigator.
  14. History of hypersensitivity or idiosyncrasy to any of the components of the investigational drug.
  15. Within 4 weeks prior to dosing, the use of:

    1. (multi)vitamins, co-enzyme Q10, Vitamin E, riboflavin, and anti-oxidant supplements (including, but not limited to idebenone/EPI-743, mitoQ); unless stable for at least one month before first dosing and remaining stable throughout the study.
    2. any medication negatively influencing mitochondrial functioning (including but not limited to valproic acid, glitazones, statins, anti-virals, amiodarone, and non-steroidal anti-inflammatory drugs (NSAIDs)), unless stable for at least one month before first dosing and remaining stable throughout the study.

      Note: thus, mitoQ and any medication negatively influencing mitochondrial functioning are allowed as long as the dose has been stable for at least one month prior to first dosing and remains stable throughout the study.

    3. any strong Cytochrome P450 (CYP)3A4 inhibitors (all 'conazoles-anti-fungals', HIV antivirals, grapefruit).
    4. strong CYP3A4 inducers (including HIV antivirals, carbamazepine, phenobarbital, phenytoin, rifampicine, St. John's wort, pioglitazone, troglitazone).
    5. any medication known to affect cardiac repolarisation (all anti-psychotics, several anti-depressants: nor/amytriptilline, fluoxetine, anti-emetics: domperidone (motilium) granisetron, ondansetron).
    6. any medication metabolised by CYP with a narrow therapeutical width.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04165239


Contacts
Layout table for location contacts
Contact: Edwin Spaans, PharmD +31 24 361 75 05 Spaans@khondrion.com
Contact: Gerrit Ruiterkamp, MSc +31 612805425 Ruiterkamp@khondrion.com

Locations
Layout table for location information
Germany
Friedrich-Baur Institut Not yet recruiting
München, Bayern, Germany, 80336
Contact: Thomas Klopstock, MD    +49 89 4400 57400      
Netherlands
Radboud University Medical Center Recruiting
Nijmegen, Netherlands
Contact: Mirian Janssen, MD, PhD    +31 24 3618819    Mirian.Janssen@radboudumc.nl   
Principal Investigator: Mirian Janssen, MD, PhD         
United Kingdom
Institute for Ageing and Health Newcastle University Not yet recruiting
Newcastle upon Tyne, United Kingdom
Contact: Gráinne Gorman, MD    +44 191 208 6365      
Sponsors and Collaborators
Khondrion BV
Julius Clinical, The Netherlands
Investigators
Layout table for investigator information
Study Director: Edwin Spaans, PharmD Khondrion BV

Layout table for additonal information
Responsible Party: Khondrion BV
ClinicalTrials.gov Identifier: NCT04165239     History of Changes
Other Study ID Numbers: KH-176-202
First Posted: November 15, 2019    Key Record Dates
Last Update Posted: November 15, 2019
Last Verified: November 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Khondrion BV:
Mitochondrial
Oxidative Phosphorylation (OXPHOS)
MELAS
MIDD
KH176
Additional relevant MeSH terms:
Layout table for MeSH terms
Mitochondrial Myopathies
MELAS Syndrome
Mitochondrial Encephalomyopathies
Mitochondrial Diseases
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Metabolic Diseases
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Cerebral Small Vessel Diseases
Cerebrovascular Disorders
Vascular Diseases
Cardiovascular Diseases
Metabolism, Inborn Errors
Genetic Diseases, Inborn